# Ascenta Capital

> Ascenta Capital is a VC fund backing Biotechnology and Health Care. See 12 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 12
- Last investment: Jun 2026
- Lead investor: 75%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/ascenta-capital
- Website: https://ascentacap.com

Ascenta Capital is a private equity and venture capital firm.

## Contacts

5 contacts available for Ascenta Capital. Shizune tracks 1 team members at Ascenta Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ascenta-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 58% |
| Health Care | 5 | 42% |
| Medical | 4 | 33% |
| Pharmaceutical | 3 | 25% |
| Biopharma | 2 | 17% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 42% |
| Series C | 5 | 42% |
| Funding Round | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 58% |
| Canada | 1 | 8% |
| Germany | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Lorence Kim | Co-founder and Managing Partner | 5 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Triveni Bio | Triveni Bio is at the forefront of human genetics, cutting-edge antibody design, and precision medicine, pioneering the identification of new disease targets. | $65M | Series C | Jun 17, 2026 |  |
| Triana Biomedicines | Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas. | $120M | Series B | Dec 03, 2025 |  |
| Iambic | The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. | $127.8M |  | Nov 10, 2025 |  |
| Tubulis | Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $400.6M | Series C | Oct 15, 2025 |  |
| Alpha-9 Oncology | Alpha9 Theranostics is a clinical-stage biopharmaceutical company. | $175M | Series C | Oct 23, 2024 |  |
| OrsoBio | OrsoBio is a clinical-stage biopharmaceutical company that creates therapies for patients suffering from severe metabolic disorders such as diabetes, severe dyslipidemia, lipodystrophies, and others. OrsoBio is committed to restoring energy homeostasis in patients with severe metabolic disorders, in some cases, by targeting pathways relevant tomaintaining energy balance. OrsoBio revolutionizes the treatment of these disorders by addressing the underlying cause. | $67M | Series B | Sep 06, 2024 |  |
| Cardurion Pharmaceuticals | Cardurion Pharmaceuticals is a Boston-based biotechnology company focused on developing novel therapeutics for the treatment of heart failure and other cardiovascular diseases. The company is advancing groundbreaking clinical programs targeting PDE9 and CaMKII inhibition, leveraging its expertise in cardiovascular signaling pathways to addressunmet patient needs. | $260M | Series B | Jul 16, 2024 |  |
| Odyssey Therapeutics | Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $101M | Series C | Dec 05, 2023 |  |
| Iambic | The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. | $100M | Series B | Oct 03, 2023 |  |
| ADARx Pharmaceuticals | ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired andfunctional protein is restored. It was founded in 2019 and is headquartered in San Diego, California. | $200M | Series C | Aug 09, 2023 |  |

10 of 12 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 5 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 4 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 3 deals together
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 3 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 3 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Ascenta Capital invest in?

Ascenta Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Ascenta Capital?

Public channels for Ascenta Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Ascenta Capital?

The team at Ascenta Capital includes Lorence Kim (Co-founder and Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co